Executive Summary
•QBE trades at ~13.4x NTM P/E on the $1.88 consensus EPS, or ~12.4x on the revised $2.03 NTM EPS, a discount to its own 2 year average P/E of 21x and broadly in line with global general insurers at 11 to 15x.
•Underwriting momentum is intact: 1H26 adjusted NPAT of US$1.03b (+3.6% YoY) and ROE of 17.7%, comfortably above the 15%+ medium term target.
•Capital returns are the key support: a $450m on market buyback running through 2026 plus a 4.64% dividend yield imply total shareholder returns near 8 to 9%.
•Valuation signals conflict: P/E and EV/EBITDA screen cheap versus history, but EV/EBIT and EV/Revenue screen expensive, so the case rests on earnings delivery rather than a re rating.
Financial Snapshot
•Revenue (TTM): $19.45b
•Gross margin: 18.0%
•Operating margin: 15.8%
•Net margin: 11.1%
•ROE: 19.3% (TTM), 17.7% (1H26)
•Debt/Equity: 37.6%
•Net debt / EV: 0.06x
•Dividend yield: 4.64%
•Market cap: $36.75b
•1H26 adjusted NPAT: US$1.03b (+3.6% YoY)
•Note: reported quarterly revenue and net income figures in the supplied data are internally inconsistent with the $19.45b TTM revenue line and are treated as unreliable.
Forward Outlook
•FY26 consensus EBIT: $3.60b
•NTM EPS: $2.03 (revised up from $1.88)
•Forward EPS growth: +5.7% YoY
•EBIT growth: +9.9% YoY
•EBITDA growth: +18.8% YoY
•FCF growth: -21.2% YoY (a cash conversion watch point)
•Consensus DPS of $0.05 in the data is inconsistent with the 4.64% yield and appears erroneous (implied DPS ~$1.17)
•Margin trajectory: ROE expected to hold in the high teens, above the 15%+ target
Valuation Analysis
•NTM P/E: ~13.4x on $1.88 EPS, ~12.4x on $2.03 EPS
•NTM P/S: ~1.6 to 1.9x (forward revenue not cleanly disclosed)
•NTM EV/EBIT: ~10.75x (Bloomberg), ~9.5x (EQRV basis)
•Trailing P/BV: 2.2x versus 2 year average 2.0x (implied value at average $22.13)
•Trailing EV/EBITDA: 9.0x versus 2 year average 13.7x (implied price at average $38.25)
•Trailing P/E: 12.0x versus 2 year average 21.1x (implied price at average $44.22)
•Consensus target price: $25.37, essentially at the current $25.17
•Relative history caution: EV/EBIT at 9.5x versus a 2 year average of 2.9x and EV/Revenue at 1.2x versus 0.7x both screen rich, suggesting the low P/E partly reflects a lower earnings base rather than pure undervaluation
•IAG: ~15x NTM P/E, Australian general insurance peer with domestic concentration
•Suncorp: ~14x NTM P/E, bancassurance plus general insurance mix
•Chubb: ~12x NTM P/E, global P&C leader, strong reserve track record
•Travelers: ~12x NTM P/E, US commercial lines benchmark
•Allianz: ~11x NTM P/E, global composite with life weighting
Key Risks & Catalysts
Risks
•Catastrophe exposure: climate driven nat cat events could pressure the combined ratio and ROE
•Reserve adequacy: prior year strengthening in North America has been a recurring earnings risk
•Premium cycle softening: decelerating commercial lines rates could slow GWP growth
•FCF growth of -21.2% consensus signals potential cash generation pressure
•Currency translation: USD denominated earnings create AUD reporting volatility
•Data quality: inconsistent quarterly disclosures reduce confidence in trend analysis
Catalysts
•$450m on market buyback running through 2026
•Sustained ROE above the 15%+ target supporting a potential re rating
•1H26 adjusted NPAT of US$1.03b, +3.6% YoY
•Appointment of Jonathan Groves as CEO Australia Pacific, a potential operational reset
•Premium rate hardening across key markets
•Upward consensus EPS revisions, from $1.88 to $2.03 NTM
Investment Thesis
QBE is a capital return story trading at a modest forward multiple. At ~12.4x NTM P/E on the revised $2.03 EPS, with a 4.64% yield and a $450m buyback, the stock offers a total return profile near 8 to 9% without requiring multiple expansion. The 17.7% 1H26 ROE confirms the business is clearing its 15%+ medium term target, and consensus EPS is being revised up, the single most supportive signal in the data set.
The valuation picture is genuinely mixed. The 12.0x trailing P/E against a 21x two year average looks compelling, but EV/EBIT and EV/Revenue both sit well above their own history, implying the low P/E reflects a depressed earnings base rather than a pure discount. This argues for caution on any re rating thesis and favours earnings delivery as the return driver.
Recommendation: Hold with a 12 month price target of $26.50, roughly 5% upside plus the dividend, applying a modest premium to the $25.37 consensus to reflect buyback support and upward EPS revisions. The risk/reward is balanced: the yield and buyback provide downside support near the $22 P/BV implied level, while the soft premium cycle and catastrophe exposure cap upside. A decisive break above the $25.83 52 week high on sustained ROE above 17% would justify upgrading to Buy.
